Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Inclusion Criteria: * Patients with initial renal cancer diagnosis * Patients diagnosed at Stage III or Stage IV (as defined in CAS): as evidence for advanced/metastatic RCC * For patients with Stage I/II or patients with missing information on Staging * Patients who received SACT1 treatment following initial renal cancer diagnosis through end of enrolment (31 July 2019) * Patients who received cabozantinib or axitinib treatment Exclusion Criteria: * Diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of aRCC * Less than 18 years of age at the time of initial aRCC diagnosis * SACT treatment more than 30 days prior to initial aRCC diagnosis